New biomarker found for group of rare metabolic diseases

August 7, 2017, Perelman School of Medicine at the University of Pennsylvania

A newly discovered biomarker associated with a rare metabolic disorder may facilitate better diagnosis and identification of new drugs for clinical trials for the disease, according to researchers in the Perelman School of Medicine at the University of Pennsylvania. Their findings are described in Human Molecular Genetics. Development of treatments for the neurological symptoms of mucopolysaccharidoses (MPS), a family of rare genetic disorders, have been hindered by the lack of objective measures of the extent of central nervous system (CNS) damage in patients.

"This new biomarker for CNS symptoms in MPS patients may help families better understand their child's diagnosis and prognosis and should help clinicians and regulatory agencies to evaluate the efficacy of new therapies," said senior author James Wilson, MD, PhD, a professor of Medicine and director of the Orphan Disease Center (ODC) at Penn.

MPS I is the most common form of this group of diseases and is caused by a deficiency of the key enzyme IDUA needed to break down complex sugars in cells. The disorder eventually leads to the abnormal accumulation of sugar fragments and cell death. The two main treatments are bone marrow transplantation and intravenous enzyme replacement therapy; however, neither of these treatments cure the disorder, especially when the disease enters the central nervous system.

Many of the individual MPS disorders share symptoms, such as vision and hearing problems, hernias, and heart problems. Patient groups estimate that in the United States 1 in 25,000 births results in some form of MPS. Life expectancy varies significantly for people with MPS, but individuals with the most severe form rarely live more than 10 years.

The ODC team screened metabolites from cerebrospinal fluid (CSF) in a canine model of MPS I. This assay revealed a marked elevation of a compound called spermine in affected animals. Gene therapy to reduce CSF spermine corrected brain lesions in these dogs.

Additional studies in cultured neurons from MPS I mice showed that elevated spermine was responsible for the abnormal overgrowth observed in the mouse cells.

In humans, spermine is elevated in the CSF of four MPS subtypes in which cognitive declines are seen, but not in two subtypes in which cognitive function is preserved. In MPS I patients, elevated CSF spermine was restricted to patients with genotypes associated with CNS disease. CSF spermine in these patients was reduced following hematopoietic stem cell transplantation—the only therapy currently capable of improving cognitive outcomes.

"Our findings offer new insights into CNS symptoms in MPS patients," said first author Christian Hinderer, MD, PhD, ODC Research Director. "These studies suggest CSF spermine could be used as a biomarker to evaluate the outcome of novel therapeutics designed to treat the CNS manifestations of MPS diseases, which will greatly simplify clinical trials."

"The mission of the ODC is to enable the development of novel diagnostics and treatments for rare diseases," Wilson said. "We are offering access to this biomarker to the orphan research community for all research purposes at no cost to enable labs to freely conduct assays for their own research and patients' needs. The only way we will move ahead in our field is to openly collaborate in the pre-competitive space, during the early stages of development of biomarkers and treatments."

Explore further: Study verifies human gene therapy in model of rare metabolic disorder

Related Stories

Study verifies human gene therapy in model of rare metabolic disorder

July 28, 2016
Researchers are closer to finding a better way to treat children with a rare metabolic disorder called MPS I. It is caused by a deficiency of the key enzyme IDUA needed to break down complex sugars in cells. MPS I eventually ...

Attacking a rare disease at its source with gene therapy

August 26, 2014
Treating the rare disease MPS I is a challenge. MPS I, caused by the deficiency of a key enzyme called IDUA, eventually leads to the abnormal accumulation of certain molecules and cell death.

Liver gene therapy corrects heart symptoms in model of rare enzyme disorder

September 29, 2014
In the second of two papers outlining new gene-therapy approaches to treat a rare disease called MPS I, researchers from Perelman School of Medicine at the University of Pennsylvania examined systemic delivery of a vector ...

Neurodegenerative disease mechanism and potential drug identified

June 6, 2017
Two new studies of progressive, neurodegenerative diseases linked to defects in cells' mitochondria offer hope for developing a new biomarker for research and diagnostics, and a drug for treating such diseases, report researchers ...

Researchers discover a new mechanism of epilepsy

November 19, 2015
In epilepsy, nerve cells lose their usual rhythm, and ion channels, which have a decisive influence on their excitability, are involved. A team of researchers under the direction of the University of Bonn has now discovered ...

Brain cell transplants could help treat Parkinson's disease

April 10, 2017
Replacing lost brain cells may help undo the damage caused by Parkinson's disease, researchers believe.

Recommended for you

Team identifies new mechanism essential for eye lens development

May 17, 2018
If you want to take clear photographs, you don't use sandpaper to clear a smudge from your camera's lens. Similarly, if you want to see clearly, the lens of your eye has to be free of obstruction.

Sugars in infant formulas pose risk to babies with inherited metabolic disorder

May 16, 2018
Babies with inherited intolerance of fructose face a risk of acute liver failure if they are fed certain widely available formulas containing fructose, pediatricians and geneticists are warning. Baby formula manufacturers ...

Researchers identify gene that helps prevent brain disease

May 16, 2018
Scientists know that faulty proteins can cause harmful deposits or "aggregates" in neurological disorders such as Alzheimer's and Parkinson's disease. Although the causes of these protein deposits remain a mystery, it is ...

New tool predicts eye, hair and skin color from a DNA sample of an unidentified individual

May 14, 2018
An international team, led by scientists from the School of Science at IUPUI and Erasmus MC University Medical Center Rotterdam in the Netherlands, has developed a novel tool to accurately predict eye, hair and skin color ...

Gene disruption signals cerebral palsy and autism link

May 10, 2018
University of Adelaide researchers have uncovered a genetic signal common to both cerebral palsy and autism.

Solving pieces of the genetic puzzle

May 10, 2018
Every living thing on the planet contains DNA, the molecular sequence that encodes the genetic blueprint of an organism. Genome sequencing can reveal your likelihood of getting certain diseases like Alzheimer's, and it can ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.